These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35323932)

  • 1. Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings.
    Chandna A; Mahajan R; Gautam P; Mwandigha L; Gunasekaran K; Bhusan D; Cheung ATL; Day N; Dittrich S; Dondorp A; Geevar T; Ghattamaneni SR; Hussain S; Jimenez C; Karthikeyan R; Kumar S; Kumar S; Kumar V; Kundu D; Lakshmanan A; Manesh A; Menggred C; Moorthy M; Osborn J; Richard-Greenblatt M; Sharma S; Singh VK; Singh VK; Suri J; Suzuki S; Tubprasert J; Turner P; Villanueva AMG; Waithira N; Kumar P; Varghese GM; Koshiaris C; Lubell Y; Burza S
    Clin Infect Dis; 2022 Aug; 75(1):e368-e379. PubMed ID: 35323932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
    Vasbinder A; Padalia K; Pizzo I; Machado K; Catalan T; Presswalla F; Anderson E; Ismail A; Hutten C; Huang Y; Blakely P; Azam TU; Berlin H; Feroze R; Launius C; Meloche C; Michaud E; O'Hayer P; Pan M; Shadid HR; Rasmussen LJH; Roberts DA; Zhao L; Banerjee M; Murthy V; Loosen SH; Chalkias A; Tacke F; Reiser J; Giamarellos-Bourboulis EJ; Eugen-Olsen J; Pop-Busui R; Hayek SS;
    J Med Virol; 2024 Jan; 96(1):e29389. PubMed ID: 38235904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.
    Stauning MA; Altintas I; Kallemose T; Eugen-Olsen J; Lindstrøm MB; Rasmussen LJH; Gamst-Jensen H; Nehlin JO; Andersen O; Tingleff J
    J Emerg Med; 2021 Sep; 61(3):298-313. PubMed ID: 34092446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of Serum Pentraxin-3 and suPAR Levels as Acute Phase Reactants in Patients with COVID-19].
    Akbayırlı U; Kaya S; Aksoy Gökmen A
    Mikrobiyol Bul; 2022 Oct; 56(4):631-644. PubMed ID: 36458710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study.
    Gupta RK; Harrison EM; Ho A; Docherty AB; Knight SR; van Smeden M; Abubakar I; Lipman M; Quartagno M; Pius R; Buchan I; Carson G; Drake TM; Dunning J; Fairfield CJ; Gamble C; Green CA; Halpin S; Hardwick HE; Holden KA; Horby PW; Jackson C; Mclean KA; Merson L; Nguyen-Van-Tam JS; Norman L; Olliaro PL; Pritchard MG; Russell CD; Scott-Brown J; Shaw CA; Sheikh A; Solomon T; Sudlow C; Swann OV; Turtle L; Openshaw PJM; Baillie JK; Semple MG; Noursadeghi M;
    Lancet Respir Med; 2021 Apr; 9(4):349-359. PubMed ID: 33444539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR.
    Kerget B; Kerget F; Aksakal A; Aşkın S; Uçar EY; Sağlam L
    J Med Virol; 2021 Sep; 93(9):5568-5573. PubMed ID: 34019703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.
    Segala FV; Rando E; Salvati F; Negri M; Catania F; Sanmartin F; Murri R; Giamarellos-Bourboulis EJ; Fantoni M
    PLoS One; 2023; 18(4):e0273202. PubMed ID: 37014833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of a Robust and Interpretable Early Triaging Support System for Patients Hospitalized With COVID-19: Predictive Algorithm Modeling and Interpretation Study.
    Baek S; Jeong YJ; Kim YH; Kim JY; Kim JH; Kim EY; Lim JK; Kim J; Kim Z; Kim K; Chung MJ
    J Med Internet Res; 2024 Jan; 26():e52134. PubMed ID: 38206673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study.
    Arnold DT; Attwood M; Barratt S; Morley A; Elvers KT; McKernon J; Donald C; Oates A; Noel A; MacGowan A; Maskell NA; Hamilton FW
    Emerg Med J; 2021 Jul; 38(7):543-548. PubMed ID: 34021028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study.
    Pan F; Yang L; Li Y; Liang B; Li L; Ye T; Li L; Liu D; Gui S; Hu Y; Zheng C
    Int J Med Sci; 2020; 17(9):1281-1292. PubMed ID: 32547323
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19.
    Sayah W; Berkane I; Guermache I; Sabri M; Lakhal FZ; Yasmine Rahali S; Djidjeli A; Lamara Mahammed L; Merah F; Belaid B; Berkani L; Lazli NZ; Kheddouci L; Kadi A; Ouali M; Khellafi R; Mekideche D; Kheliouen A; Hamidi RM; Ayoub S; Raaf NB; Derrar F; Gharnaout M; Allam I; Djidjik R
    Cytokine; 2021 May; 141():155428. PubMed ID: 33550165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.
    Giamarellos-Bourboulis EJ; Poulakou G; de Nooijer A; Milionis H; Metallidis S; Ploumidis M; Grigoropoulou P; Rapti A; Segala FV; Balis E; Giannitsioti E; Rodari P; Kainis I; Alexiou Z; Focà E; Lucio B; Rovina N; Scorzolini L; Dafni M; Ioannou S; Tomelleri A; Dimakou K; Tzatzagou G; Chini M; Bassetti M; Trakatelli C; Tsoukalas G; Selmi C; Samaras C; Saridaki M; Pyrpasopoulou A; Kaldara E; Papanikolaou I; Argyraki A; Akinosoglou K; Koupetori M; Panagopoulos P; Dalekos GN; Netea MG
    Cell Rep Med; 2022 Mar; 3(3):100560. PubMed ID: 35474750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.
    Sarif J; Raychaudhuri D; D'Rozario R; Bandopadhyay P; Singh P; Mehta P; Hoque MA; Sinha BP; Kushwaha M; Sahni S; Devi P; Chattopadhyay P; Paul SR; Ray Y; Chaudhuri K; Banerjee S; Majumdar D; Saha B; Sarkar BS; Bhattacharya P; Chatterjee S; Paul S; Ghosh P; Pandey R; Sengupta S; Ganguly D
    Front Immunol; 2021; 12():738093. PubMed ID: 34777349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants.
    Paranga TG; Pavel-Tanasa M; Constantinescu D; Plesca CE; Petrovici C; Miftode IL; Moscalu M; Cianga P; Miftode EG
    Front Immunol; 2023; 14():1213246. PubMed ID: 37388734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
    Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
    Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
    Oulhaj A; Alsuwaidi AR; Suliman A; Gasmelseed H; Khan S; Alawi S; Hukan Y; George J; Alshamsi F; Sheikh F; Babiker ZOE; Prattes J; Sourij H
    Int J Infect Dis; 2021 Jun; 107():188-194. PubMed ID: 33862208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6-based mortality risk model for hospitalized patients with COVID-19.
    Laguna-Goya R; Utrero-Rico A; Talayero P; Lasa-Lazaro M; Ramirez-Fernandez A; Naranjo L; Segura-Tudela A; Cabrera-Marante O; Rodriguez de Frias E; Garcia-Garcia R; Fernández-Ruiz M; Aguado JM; Martinez-Lopez J; Lopez EA; Catalan M; Serrano A; Paz-Artal E
    J Allergy Clin Immunol; 2020 Oct; 146(4):799-807.e9. PubMed ID: 32710975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open label trial of anakinra to prevent respiratory failure in COVID-19.
    Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
    Elife; 2021 Mar; 10():. PubMed ID: 33682678
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.